Search Within

Renata Panchal

Formats
  1. Meeting Abstract (5)
  2. Journal Article (1)
Groups
  1. Biostatistics Service (4)
  2. Epidemiology and Biostatistics (4)
  3. Multidisciplinary Brain Metastasis Program (4)
  4. Population Sciences Research Program (4)
  5. Tow Center for Developmental Oncology (TCDO) (4)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (3)

More Groups

People
  1. Antonio Omuro (4)
  2. Denise Correa (4)
  3. Katherine Panageas (4)
  4. Kathryn Beal (4)
  5. Lauren Abrey (4)
  6. Lisa De Angelis (4)

More People

Years
  1. 2024 (1)
  2. 2023 (1)
  3. 2014 (1)
  4. 2011 (3)
Publications
  1. Journal of Clinical Oncology (3)
  2. Neuro-Oncology (2)
  3. Clinical Cancer Research (1)
Publishers
  1. American Society of Clinical Oncology (3)
  2. Oxford University Press (2)
  3. American Association for Cancer Research (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Use of an application that extracts and consolidates adverse events and concomitant medication data from clinical systems to increase clinical trial data entry efficiency, trust, and satisfaction
    Meeting Abstract

    Yuravlivker, L.; Kim, B. Y.; Buckley, M. T.; Bouvier, N.; Panchal, R.; Lengfellner, J. M.; Delgado, C.; Terzulli, S. L.; Sabbatini, P.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Integrating technology to support data management abstraction of adverse events (AE) and concomitant medications (ConMed) from the electronic health record (EHR) to sponsor electronic data capture (EDC) systems using design thinking (DT) methodology
    Meeting Abstract

    Yuravlivker, L.; Buckley, M. T.; Bouvier, N.; Jeevarathnam, S.; Lazan, S.; Panchal, R.; McKellop, M.; Lengfellner, J. M.; Terzulli, S. L.; Sabbatini, P.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma
    Journal Article

    Omuro, A.; Beal, K.; Gutin, P.; Karimi, S.; Correa, D. D.; Kaley, T. J.; Deangelis, L. M.; Chan, T. A.; Gavrilovic, I. T.; Nolan, C.; more...
    Clinical Cancer Research (2014)

    Fulltext@MSK | Save
  • Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM)
    Meeting Abstract

    Omuro, A. M. P.; Beal, K.; Karimi, S.; Correa, D.; Chan, T. A.; DeAngelis, L. M.; Gavrilovic, I. T.; Nolan, C.; Hormigo, A.; Lassman, A. B.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Longitudinal cognitive follow-up in newly diagnosed glioblastoma patients treated with bevacizumab, temozolomide and hypofractionated stereotactic radiotherapy
    Meeting Abstract

    Correa, D. D.; Baser, R.; Beal, K.; Karimi, S.; DeAngelis, L.; Panageas, K.; Barradas, R.; Statucka, M.; Abrey, L.; Gutin, P.; more...
    Neuro-Oncology (2011)

    Fulltext@MSK | Save
  • Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma
    Meeting Abstract

    Omuro, A.; Beal, K.; Correa, D.; Chan, T.; DeAngelis, L.; Gavrilovic, I.; Nolan, C.; Hormigo, A.; Lassman, A. B.; Kaley, T.; more...
    Neuro-Oncology (2011)

    Fulltext@MSK | Save